Having kicked off its late-stage clinical program for lead candidate opelconazole, the UK's Pulmocide Ltd has secured fresh funding to advance the antifungal for the treatment of invasive pulmonary aspergillosis (IPA).
The London-headquartered respiratory specialist has extended the $92m series C financing unveiled in May last year with a $52m extension...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?